# Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

> **NCT00267930** · PHASE2 · COMPLETED · sponsor: **Advanz Pharma** · enrollment: 221 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Vernakalant (oral)
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT00267930
- **Lead sponsor:** Advanz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2008-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267930, "Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00267930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*